Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration
18 Junio 2018 - 7:30AM
Pascal Biosciences Inc. (TSX-V:PAS) (
Pascal), is
pleased to announce significant progress in its cannabinoid based
research and development program with the University of British
Columbia (
UBC). Pascal has been licensed by the US
Drug Enforcement Administration (
DEA) to conduct
research and development on cannabinoids. Pascal is also pleased to
renew the UBC collaboration and continue financial support of Dr.
Wilfred Jefferies’ laboratory at the Michael Smith Laboratories.
Pascal is one of only a few organizations with a Schedule I
Researcher license in the United States that is not a university.
Obtaining a DEA Schedule I Researcher license is a rigorous
process, requiring a well-documented line of scientific
investigation in a formal application, inspection of laboratory
facilities, review of Pascal’s plans for record-keeping, and
confirmation of facility security. “Receiving our Schedule I DEA
license allows us to immediately conduct advanced R&D on
cannabinoids, with a goal of conducting clinical trials on cancer
patients as soon as possible”, commented Dr. Patrick Gray, CEO at
Pascal.
Dr. Jeffries was the first scientist to discover specific
cannabinoids that can increase the immune recognition of both mouse
and human cancer cells. Together, both labs have greatly extended
this work. Over 375 natural and synthetic cannabinoids have been
tested, and the most potent and safe cannabinoids have been
identified. “Previous support by Pascal enabled the discovery of
specific cannabinoids that enhance detection and elimination of
cancers by the immune system”, commented Dr. Jefferies. “Together
we have made great progress in developing a cannabinoid for cancer.
Pascal’s continued financial support will enable a lead product to
complete preclinical efforts for treatment of patients with
cancer.”
In order to undertake this work, both the Pascal development lab
in Seattle and Dr. Jefferies’ lab in Vancouver, BC were required to
be licensed by the appropriate government agencies. In addition to
Pascal being awarded the Schedule I Researcher license by the U.S.
DEA, Dr. Jefferies’ lab has received approval from Health Canada
for an exemption under Section 56 of the Controlled Drugs and
Substances Act. This approval allows the lab to utilize
controlled substances for research and development purposes and to
test cannabinoid compounds in cell-based studies and in animal
models of human diseases.
Cannabinoids have previously been used in the treatment of
cancer symptoms, including nausea, appetite enhancement, and pain
management. However, Pascal is the first to identify a mechanism by
which cannabinoids may provide a direct benefit in immunotherapy.
This discovery may enhance the performance of other cancer
therapeutics such as checkpoint inhibitors, which activate the
immune system to destroy cancer cells.
ABOUT UBC AND THE VANCOUVER PROSTATE CENTREIn
addition to his role as Professor at the UBC Michael Smith
Laboratories, Dr. Wilfred Jefferies is the scientific founder of
Pascal and the Head of the Immune Oncology program in the Vancouver
Prostate Centre.
The University of British Columbia is a global centre for
research and teaching, consistently ranked among the 40 best
universities in the world. Since 1915, UBC’s West Coast spirit has
embraced innovation and challenged the status quo. Its
entrepreneurial perspective encourages students, staff and faculty
to challenge convention, lead discovery and explore new ways of
learning. At UBC, bold thinking is given a place to develop into
ideas that can change the world.
To learn more, visit: www.ubc.ca
The Vancouver Prostate Centre is a research hub hosted by UBC
and Vancouver Coastal Health Research Institute and designated
National Centre of Excellence for Commercialization and Research.
The Vancouver Prostate Centre (VPC) has a track
record of success that has earned it a reputation as one of the
world’s most respected cancer facilities. The combination of a
large patient clinic and clinical trials facility, together with a
world-class translational research program under the same roof,
make the VPC the largest program of its kind in Canada. To learn
more, visit: www.prostatecentre.com
ABOUT PASCAL BIOSCIENCES INC. Pascal
Biosciences, Inc. is a drug discovery and development company
focused on harnessing the body’s immune system to fight cancer. The
Company’s three significant technologies are:
- Utilizing proprietary screening systems for
identifying novel compounds that are able to restore immune
recognition and killing of cancer cells;
- Exploiting the regulation of specific calcium channels
expressed by cells of the immune system. By regulating these
calcium channels, immune activity can be controlled to combat
cancers, infections and autoimmune diseases;
- Developing a therapeutic monoclonal antibody for B-cell
precursor acute lymphoblastic leukemia, the most common childhood
leukemia, in collaboration with the University of New Mexico.
To learn more, visit: https://www.pascalbiosciences.com/.
On Behalf of the Board of DirectorsDr. Patrick W. Gray,
President & CEO
Company Contact: Dr. Karina LealTel:
206-221-3443
Investors:invest@pascalbiosciences.comTel:
206-221-3443
DISCLAIMER
Certain statements in this press release contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 or forward-looking
information under applicable Canadian securities legislation that
may not be based on historical fact, including without limitation
statements containing the words “believe”, “may”, “plan”, “will”,
“estimate”, “continue”, “anticipate”, “intend”, “expect” and
similar expressions. Such forward-looking statements or information
involve known and unknown risks, uncertainties and other factors
that may cause our actual results, events or developments, or
industry results, to be materially different from any future
results, events or developments express or implied by such
forward-looking statements or information. Such factors include,
among others, our stage of development, lack of any product
revenues, additional capital requirements, risk associated with the
completion of clinical trials and obtaining regulatory approval to
market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects
for negotiating additional corporate collaborations or licensing
arrangements and their timing. Specifically, certain risks and
uncertainties that could cause such actual events or results
expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include,
but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials,
or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not
be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the
costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and
other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
“Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release”
Pascal Biosciences (TSXV:PAS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Pascal Biosciences (TSXV:PAS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024